Cognate BioServices announces acquisition of Cobra Biologics Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products EW Healthcare Partners and its co-investors provide the financing for the transaction MEMPHIS, Tenn., Nov. 4, 2019/PRNewswire/ — Cognate BioServices (Cognate), a leading contract […]
Read more →Cognate BioServices Secures Growth Capital Investment from EW Healthcare to Continue to Expand Commercial Manufacturing Capacity and Services for the Cellular Therapies Industry BALTIMORE & MEMPHIS, Tenn.–(BUSINESS WIRE)–Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, announced today it […]
Read more →Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina BASKING RIDGE, NJ, AND MEMPHIS, TENN. (August 7, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company […]
Read more →Memphis, June 10, 2019 – Cognate BioServices, Inc., a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, today announced that It has received a statement of compliance for the manufacture and development of advanced therapy medicinal products (ATMPs) for EU/UK. “We’re […]
Read more →Memphis, TN & Menlo Park, CA. January 22nd, 2019 – Cognate BioServices, Inc., a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, today announced a letter of intent for a collaboration with Astero Bio Corporation, a leader in the development of innovative […]
Read more →Memphis, TN September 28th, 2018 – Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, today announced a letter of intent for a collaboration agreement with Terumo BCT, a leading technology provider in the cell therapy market. Under the terms […]
Read more →Cognate BioServices and FloDesign Sonics Announce Collaboration to Advance Acoustic Cell Processing as a Platform for Cell Therapy Manufacturing Wilbraham, MA, September 4, 2018 – FloDesign Sonics, a global leader in acoustic cell processing for cell and gene therapies, and Cognate BioServices, a leading contract development and […]
Read more →Cognate Completes Management Buyout and Raises Growth Capital to Fund Commercial Cellular Therapy Manufacturing Expansion BALTIMORE, MD and MEMPHIS, TN – Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, announced today it has completed a management buyout (“MBO”) […]
Read more →